



## Correction to: Human skin-derived ABCB5<sup>+</sup> stem cell injection improves liver disease parameters in *Mdr2KO* mice

Vanessa Hartwig<sup>1</sup> · Bedair Dewidar<sup>1,2</sup> · Tao Lin<sup>1</sup> · Anne Dropmann<sup>1</sup> · Christoph Ganss<sup>3,4</sup> · Mark Andreas Kluth<sup>3,4</sup> · Nils Tappenbeck<sup>3</sup> · Lysann Tietze<sup>5</sup> · Bruno Christ<sup>5</sup> · Markus Frank<sup>6</sup> · Roger Vogelmann<sup>1</sup> · Matthias Philip Alexander Ebert<sup>1</sup> · Steven Dooley<sup>1</sup> 

Received: 16 October 2019 / Accepted: 16 October 2019 / Published online: 29 October 2019  
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

**Correction to: Archives of Toxicology (2019) 93:2645–2660**  
<https://doi.org/10.1007/s00204-019-02533-3>

We wish to submit a corrigendum to the above-mentioned article. Thank you very much for consideration and publication.

**Conflict of interest** Vanessa Hartwig, Steven Dooley, Lysann Tietze and Bruno Christ participate in corporate-sponsored research collaborations with RHEACELL GmbH and Co. KG (Heidelberg, Germany). Christoph Ganss is CEO and Mark A. Kluth is CSO of RHEACELL and TICEBA GmbH (Heidelberg, Germany). Nils Tappenbeck

is project manager at RHEACELL. Markus H. Frank is an inventor of ABCB5-related United States and international patents assigned to Boston Children’s Hospital and/or Brigham and Women’s Hospital (Boston, Massachusetts) and licensed to TICEBA and RHEACELL and serves as a scientific advisor to TICEBA and RHEACELL. The remaining authors have no conflicting interests. Data and data presentation are uninfluenced by TICEBA and RHEACELL.

Then in the abstract of the manuscript, “resulted from ABCB5<sup>+</sup> cell **transformation**” should be “resulted from ABCB5<sup>+</sup> cell **transplantation**”.

The original article can be found online at <https://doi.org/10.1007/s00204-019-02533-3>.

✉ Steven Dooley  
steven.dooley@medma.uni-heidelberg.de

Vanessa Hartwig  
vanessa.hartwig@medma.uni-heidelberg.de

Bedair Dewidar  
bedair.dewidar@medma.uni-heidelberg.de

Tao Lin  
tao.lin@medma.uni-heidelberg.de

Anne Dropmann  
anne.dropmann@medma.uni-heidelberg.de

Christoph Ganss  
christoph.ganss@rheacell.com

Mark Andreas Kluth  
andreas.kluth@ticeba.com

Nils Tappenbeck  
nils.tappenbeck@rheacell.com

Lysann Tietze  
lysann.tietze@medizin.uni-leipzig.de

Bruno Christ  
bruno.christ@medizin.uni-leipzig.de

Markus Frank  
markus.frank@childrens.harvard.edu

Roger Vogelmann  
roger.vogelmann@medma.uni-heidelberg.de

Matthias Philip Alexander Ebert  
matthias.ebert@medma.uni-heidelberg.de

<sup>1</sup> Section Molecular Hepatology, Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

<sup>2</sup> Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt

<sup>3</sup> RHEACELL GmbH and Co. KG, 69120 Heidelberg, Germany

<sup>4</sup> TICEBA GmbH, 69120 Heidelberg, Germany

<sup>5</sup> Applied Molecular Hepatology, Department of Visceral Transplantation, Thoracic und Vascular Surgery, Leipzig University, 04103 Leipzig, Germany

<sup>6</sup> Department of Pediatrics and Dermatology, Harvard Medical School, Boston, MA 02115, USA

Additionally, amongst the list of authors, “Markus Frank” should be “Markus Hermann Frank”.

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.